NCT04120506: An overdue trial by Shaare Zedek Medical Center
This trial is overdue. It was due to report 7 years, 2 months ago.
Think we've made a mistake? Before contacting us, review the criteria in our paper. In particular, bear in mind the following:
- We can only rely on the structured data that sponsors put into the registry: they may enter incorrect or incomplete data.
- Reporting in a journal is not enough. The FDAAA rules state that the trial must be reported on ClinicalTrials.gov.
- Terminated trials are required to report results. Only withdrawn trials (which never recruited a single patient) are not.
Full data
| Full entry on ClinicalTrials.gov | NCT04120506 |
|---|---|
| Title | Long Term Impact of Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV) in Adult Patients With Type 1 Gaucher Disease, Previously on a Stable Dose of VPRIV for at Least 3 Months: an Extension of the Investigator-initiated Study |
| Results Status | Overdue |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Jan. 10, 2016 |
| Completion date | Jan. 20, 2017 |
| Required reporting date | Jan. 20, 2018, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | April 2, 2025 |
| Days late | 2629 |